Peanut-specific immune response

The peanut-specific immune response is a pathological immunological process characterized by a Type I hypersensitivity reaction to proteins found in peanuts, most notably Ara h 1, Ara h 2, and Ara h 3 (Sampson et al., 2018, JACI). In sensitized individuals, the immune system produces allergen-specific IgE antibodies that bind to high-affinity receptors (FceRI) on the surface of mast cells and basophils. Upon re-exposure to peanut proteins, these allergens cross-link the IgE molecules, triggering the rapid release of inflammatory mediators such as histamine and leukotrienes (Wood et al., 2024, NEJM). This cascade results in clinical symptoms that can range from mild cutaneous reactions to life-threatening systemic anaphylaxis. Therapeutic strategies to manage this response include oral immunotherapy (OIT), such as peanut allergen powder-dnfp (Palforzia), which aims to induce desensitization by gradually increasing the threshold of allergen exposure (FDA, 2020). Additionally, monoclonal antibodies like omalizumab (Xolair) are utilized to neutralize circulating IgE, while agents like dupilumab target the IL-4 and IL-13 signaling pathways to inhibit the underlying Th2-mediated allergic inflammation (Wood et al., 2024, NEJM). Monitoring the efficacy of these treatments often involves measuring changes in peanut-specific IgE and IgG4 levels, as well as assessing basophil activation (Sampson et al., 2018, JACI).

Other names

Peanut allergyPeanut hypersensitivityArachis hypogaea allergyIgE-mediated peanut allergy

Oral immunotherapy (OIT) induces immunological desensitization and potential tolerance by modulating T-cell responses and increasing the threshold for allergen-induced mast cell degranulation, while monoclonal antibodies neutralize circulating IgE or block Th2-mediated cytokine signaling (IL-4/IL-13) to prevent the allergic cascade.